Metsera, Inc. (MTSR) Price & Analysis

Compare

96 Followers

MTSR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$12.30 - $47.40

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.17M

Market Cap

$3.24B

Enterprise Value$2.45B

Total Cash (Recent Filing)$530.92M

Total Debt (Recent Filing)$1.06M

Price to Earnings (P/E)―

Beta1.80

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding105,055,534

10 Day Avg. Volume1,580,581

30 Day Avg. Volume1,172,653

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)9.69

Price to Sales (P/S)0.00

P/FCF Ratio-27.82

Enterprise Value/Market Cap0.76

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-204.55K

Enterprise Value/Ebitda-8.84

Forecast

1Y Price Target

$57.33

Price Target Upside85.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsFaster-than-expected enrollment in clinical trials is seen as a positive sign for MTSR's clinical trial execution.

Market OpportunityMetsera is breaking into the obesity market, which is expected to reach $170 billion by 2030, offering significant growth potential.

Product EfficacyStrong efficacy exceeding 20% weight loss is anticipated to result in a 25% upside.

Bears Say

Competitive LandscapeMET-233i is also important as it will compete in a space where the playing field is less crowded and more level across competitors.

Financial StabilityMetsera is well-funded with enough cash to last through 2026, providing stability as they advance their clinical trials.

Product DevelopmentMetsera's lead obesity assets are novel injectables with long half-lives, offering no need for dose changes during the initial phase and convenient monthly dosing during the maintenance phase.

Metsera, Inc. News

Metsera reports Q2 EPS (66c), consensus (68c)

Cash and cash equivalents were $530.9M as of June 30, compared to $352.4M as of December 31, 2024....

18d ago

MTSR

Metsera price target raised to $45 from $38 at BofA

BofA raised the firm’s price target on Metsera (MTSR) to $45 from $38 and keeps a Buy rating...

26d ago

MTSR

Metsera, Inc. Reports Q2 2025 Financial Progress

Metsera, Inc. ( ($MTSR) ) has released its Q2 earnings. Here is a breakdown of the information Metsera,...

12d ago

MTSR

Metsera, Inc. Poised for Growth: Anticipated Catalysts and Clinical Trial Success Drive Buy Rating

Metsera, Inc., the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Cerena Chen from...

17d ago

MTSR

Metsera, Inc.: Buy Rating Affirmed Amid Promising Clinical Data and Strategic Positioning

Analyst Tim Anderson of Bank of America Securities reiterated a Buy rating on Metsera, Inc., boosting the price...

26d ago

MTSR

Metsera initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Corinne Johnson started Metsera (MTSR) with an Early-Stage Biotech rating. Published first on TheFly –...

1M ago

MTSR

Circle initiated, Charter upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

CPB

Metsera initiated with an Overweight at Wells Fargo

Wells Fargo analyst Cerena Chen initiated coverage of Metsera (MTSR) with an Overweight rating and $65 price target...

2M ago

MTSR

Metsera price target raised to $62 from $56 at Guggenheim

Guggenheim raised the firm’s price target on Metsera (MTSR) to $62 from $56 and keeps a Buy rating...

2M ago

MTSR

Metsera obesity monotherapy data ‘looks competitive,’ says BofA

After Metsera (MTSR) announced results for its ultra long-acting injectable amylin MET-233i for obesity, BofA noted that MET-233i...

2M ago

MTSR

Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz

The major averages were mixed near noon as investors are eyeing more details on the latest trade negotiations...

2M ago

CCJ

COE

Morning Movers: Warner Bros. Discovery climbs after plans to separate

Stock futures are pointing slightly higher this morning as the rebound in job growth reported on Friday has...

2M ago

COE

GHM

Metsera, Inc. Reports Positive Phase 1 Trial Results

An update from Metsera, Inc. ( ($MTSR) ) is now available. On June 9, 2025, Metsera, Inc. announced...

2M ago

MTSR

Metsera announces topline data from Phase 1 trial of MET-233i

Metsera (MTSR) announced topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog...

2M ago

MTSR

MTSR FAQ

What was Metsera, Inc.’s price range in the past 12 months?

Metsera, Inc. lowest stock price was $12.30 and its highest was $47.40 in the past 12 months.

What is Metsera, Inc.’s market cap?

Metsera, Inc.’s market cap is $3.24B.

When is Metsera, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Metsera, Inc.’s earnings last quarter?

Metsera, Inc. released its earnings results on May 12, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.945 by -$0.085.

Is Metsera, Inc. overvalued?

According to Wall Street analysts Metsera, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Metsera, Inc. pay dividends?

Metsera, Inc. does not currently pay dividends.

What is Metsera, Inc.’s EPS estimate?

Metsera, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Metsera, Inc. have?

Metsera, Inc. has 105,055,534 shares outstanding.

What happened to Metsera, Inc.’s price movement after its last earnings report?

Metsera, Inc. reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.945. Following the earnings report the stock price went down -5.732%.

Which hedge fund is a major shareholder of Metsera, Inc.?

Currently, no hedge funds are holding shares in MTSR

Metsera, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

172.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Metsera, Inc.

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

Metsera, Inc. (MTSR) Earnings & Revenues

Historic Earnings Reports

MTSR Stock 12 Month Forecast

Average Price Target

$57.33

▲(85.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","33":"$33","44":"$44","55":"$55","66":"$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,33,44,55,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.88,29.81230769230769,32.744615384615386,35.676923076923075,38.60923076923077,41.541538461538465,44.473846153846154,47.40615384615385,50.338461538461544,53.27076923076923,56.20307692307692,59.13538461538462,62.06769230769231,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.88,29.22230769230769,31.564615384615383,33.90692307692308,36.24923076923077,38.59153846153846,40.933846153846154,43.276153846153846,45.61846153846154,47.96076923076923,50.30307692307692,52.645384615384614,54.98769230769231,{"y":57.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.88,28.273846153846154,29.667692307692306,31.06153846153846,32.45538461538462,33.84923076923077,35.24307692307693,36.636923076923075,38.03076923076923,39.424615384615386,40.818461538461534,42.21230769230769,43.606153846153845,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.8,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >